<DOC>
	<DOCNO>NCT00222092</DOCNO>
	<brief_summary>Octreotide , somatostatin pentoxyfilline commercially available drug use various clinical situation . They safe know year . Octreotide somatostatin use many study prophylaxis treatment pancreatitis post-ERCP pancreatitis , pentoxyfilline show effect patient alcoholic hepatitis , obstructive vasculitis etc . The aim study evaluate efficacy treatment prophylaxis treatment post-ERCP pancreatitis . In addition molecular marker acute chronic inflammation measure endoscopic procedure accord study protocol .</brief_summary>
	<brief_title>Somatostatin , Octreotide , Pentoxyfilline Prevention Post-ERCP Pancreatitis Molecular Markers</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>patient undergo endoscopic retrograde cholangiopancreatography child , pregnant breastfeed woman patient coagulation disorder inability access papilla Vater due technical difficulty ( previous surgery , malignant obstruction )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>post-ERCP pancreatitis</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>prognosis</keyword>
	<keyword>natural course</keyword>
	<keyword>molecular marker</keyword>
</DOC>